Triple Negative Breast Neoplasms: all 1,163 studies

Page 7 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)CompletedNCT02402764Phase 2Results posted
• Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid TumorsCompletedNCT02401347Phase 2Results posted
• A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerCompletedNCT02370238Phase 2Results posted
• Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)TerminatedNCT02368691Phase 2Results posted
• A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadTerminatedNCT02322814Phase 2Results posted
• Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast CancerActive, not recruitingNCT02315196Phase 2Results posted
• A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast CancerCompletedNCT02301988Phase 2Results posted
• A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch AlterationsTerminatedNCT02299635Phase 2Results posted
• A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)CompletedNCT02259114Phase 1Results posted
• A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate CancerTerminatedNCT02203513Phase 2Results posted
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersCompletedNCT02178722Phase 1/2Results posted
• Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast CancerCompletedNCT02158507Not applicableResults posted
• Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor ActivityTerminatedNCT02124902Phase 2Results posted
• Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast CancerCompletedNCT02101385Phase 2Results posted
• A Study Of PF-06647263 In Patients With Advanced Solid TumorsTerminatedNCT02078752Phase 1Results posted
• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast CancerCompletedNCT01997333Phase 2Results posted
• Cisplatin vs Paclitaxel for Triple Negative Breast CancerCompletedNCT01982448Phase 2Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01964924Phase 2Results posted
• NECTAR Everolimus Plus Cisplatin in Triple (-) Breast CancerCompletedNCT01931163Phase 2Results posted
• Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast CancerStatus unknownNCT01928680Phase 2Results posted
• A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)CompletedNCT01920061Phase 1Results posted
• GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast CancerTerminatedNCT01918306Phase 1/2Results posted
• Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerCompletedNCT01889238Phase 2Results posted
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)CompletedNCT01881230Phase 2/3Results posted
• Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast CancerCompletedNCT01818063Phase 2Results posted
• MRI and Mammography Before Surgery in Patients With Stage I-II Breast CancerCompletedNCT01805076Phase 3Results posted
• MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentCompletedNCT01770353Phase 1Results posted
• Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast CancerCompletedNCT01750073Phase 2Results posted
• Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast CancerTerminatedNCT01745367Phase 2Results posted
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted
• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast CancerCompletedNCT01617668Phase 2Results posted
• Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast CancerActive, not recruitingNCT01525966Phase 2Results posted
• A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced CancersCompletedNCT01451632Phase 1Results posted
• A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast CancerCompletedNCT01421472Phase 2Results posted
• Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast CancerCompletedNCT01307891Phase 2Results posted
• Phase II ABT-888 With CyclophosphamideCompletedNCT01306032Phase 2Results posted
• Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by SurgeryTerminatedNCT01234532Phase 2Results posted
• Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast CancerTerminatedNCT01167192Phase 2Results posted
• Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast CancerTerminatedNCT01151449Phase 2Results posted
• Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast CancerActive, not recruitingNCT01116648Phase 1/2Results posted
• Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast CancerCompletedNCT01111825Phase 1/2Results posted
• Neo-Adjuvant Study in Triple Negative Breast Cancer PatientsCompletedNCT01097642Phase 2Results posted
• A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast CancerCompletedNCT01094184Phase 4Results posted
• Brostallicin and Cisplatin in Treating Patients With Metastatic Breast CancerCompletedNCT01091454Phase 2Results posted
• Estrogen for Triple Negative Breast CancerTerminatedNCT01083641Phase 2Results posted
• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsCompletedNCT01074970Phase 2Results posted
• Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast CancerCompletedNCT00887575Phase 1/2Results posted
• Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by SurgeryCompletedNCT00861705Phase 2Results posted
• Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer PatientsTerminatedNCT00817531Phase 2Results posted
• Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast CancerCompletedNCT00733408Phase 2Results posted
• Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast CancerCompletedNCT00679783Phase 2Results posted
• Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast CancerTerminatedNCT00603408Phase 2Results posted
• Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast CancerTerminatedNCT00542191Phase 2Results posted
• A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast CancerCompletedNCT00371254Phase 2Results posted
• A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBCCompletedNCT07827079Phase 2
• Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant ChemotherapyCompletedNCT07820228
• Survival Outcomes of Residual Disease in Triple-Negative Breast CancerCompletedNCT07714382
• Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast CancerActive, not recruitingNCT07498400Not applicable
• Metabolic Flexibility in Patients With Early Triple-negative Breast CancerActive, not recruitingNCT07484776Not applicable
• Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and EfficacyActive, not recruitingNCT07471815Phase 2
• Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01)Active, not recruitingNCT07421479
• Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast CancerWithdrawnNCT07226102Not applicable
• Axillary Nodal Burden in HER2+ and TNBCCompletedNCT07211451
• Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast CancerCompletedNCT07143097Phase 2
• Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast CancerWithdrawnNCT07136493Not applicable
• Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnNCT07134556Phase 2
• Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT07092254
• Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast CancerActive, not recruitingNCT07046195
• A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsActive, not recruitingNCT07038369Phase 1
• Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerActive, not recruitingNCT07018427
• Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant ChemotherapyCompletedNCT06965361
• A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
• A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerTerminatedNCT06878248Phase 1
• A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)WithdrawnNCT06829199Phase 2
• Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer PatientsActive, not recruitingNCT06782698Not applicable
• Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsActive, not recruitingNCT06781983Phase 1
• Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP)Active, not recruitingNCT06618014Phase 2
• Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsActive, not recruitingNCT06617169Phase 1
• TNBC Gut Microbiota During Neoadjuvant TreatmentWithdrawnNCT06610097Not applicable
• Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast CancerCompletedNCT06604858Phase 2
• Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerWithdrawnNCT06590558Phase 1
• Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor MalignanciesActive, not recruitingNCT06577987Phase 1
• A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerTerminatedNCT06568692Phase 2
• A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid TumorsActive, not recruitingNCT06533059Phase 1
• FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingNCT06519370Phase 3
• Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line TreatmentTerminatedNCT06505018Not applicable
• Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyActive, not recruitingNCT06449222Phase 2
• PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBCActive, not recruitingNCT06419621Phase 3
• Prediction of Radiotherapy Efficacy in Patients With Triple-negative Breast CancerActive, not recruitingNCT06418126Not applicable
• A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsCompletedNCT06399757Phase 1
• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Active, not recruitingNCT06382142Phase 3
• Inosine Reverse Chemo Resistance in Triple Negative Breast CancerCompletedNCT06355024Phase 2
• ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBCTerminatedNCT06351332Phase 1
• Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsActive, not recruitingNCT06337084Phase 1
• Carbonic Anhydrase IX Enzyme in Triple Negative Breast CarcinomaCompletedNCT06309459
• NM32-2668 in Adult Patients With Selected Advanced Solid TumorsTerminatedNCT06299163Phase 1
• A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingNCT06279364Phase 3
• A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid TumorsCompletedNCT06273852Early Phase 1
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsTerminatedNCT06264921Phase 1
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1

← Triple Negative Breast Neoplasms overview